development: we expect open label clinical data Q1 2019 veru Successful pre-IND meeting with FDA 9/18 IND and Phase 1/2 expected calendar Q4 2018- Johns Hopkins Cancer Center (lead center) Men with metastatic castration resistant prostate cancer who have progressed on novel androaen blocking agent (either enzalut